{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:55:02Z","timestamp":1783727702007,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Theragenics Corp."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"DOI":"10.1186\/s12877-025-06883-9","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T11:27:30Z","timestamp":1765798050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term prostate cancer survival outcomes including patterns of death in men >=75 years of age treated with low dose rate brachytherapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Shalini","family":"Moningi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grgur","family":"Miri\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Galbreath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Fiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Wallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlay","family":"Sayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Orio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"2","key":"6883_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/21681805.2017.1421260","volume":"52","author":"S L\u00f6ffeler","year":"2018","unstructured":"L\u00f6ffeler S, Halland A, Weedon-Fekj\u00e6r H, Nikitenko A, Ellingsen CL, Haug ES. High Norwegian prostate cancer mortality: evidence of over-reporting. Scand J Urol. 2018;52(2):122\u20138. https:\/\/doi.org\/10.1080\/21681805.2017.1421260.","journal-title":"Scand J Urol"},{"key":"6883_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctro.2022.04.006","volume":"35","author":"D Marotte","year":"2022","unstructured":"Marotte D, Chand-Fouche ME, Boulahssass R, Hannoun-Levi JM. Irradiation of localized prostate cancer in the elderly: a systematic literature review. Clin Transl Radiat Oncol. 2022;35:1\u20138. https:\/\/doi.org\/10.1016\/j.ctro.2022.04.006.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"18","key":"6883_CR3","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1001\/archinte.167.18.1944","volume":"167","author":"A Merglen","year":"2007","unstructured":"Merglen A, Schmidlin F, Fioretta G, Verkooijen HM, Rapiti E, Zanetti R, et al. Short- and long-term mortality with localized prostate cancer. Arch Intern Med. 2007;167(18):1944\u201350. https:\/\/doi.org\/10.1001\/archinte.167.18.1944.","journal-title":"Arch Intern Med"},{"issue":"1","key":"6883_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.eururo.2014.12.026","volume":"68","author":"O Bratt","year":"2015","unstructured":"Bratt O, Folkvaljon Y, Hj\u00e4lm Eriksson M, Akre O, Carlsson S, Drevin L, et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol. 2015;68(1):53\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2014.12.026.","journal-title":"Eur Urol"},{"issue":"2","key":"6883_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00345-018-2389-1","volume":"37","author":"W Sheng","year":"2019","unstructured":"Sheng W, Kirschner-Hermanns R, Zhang H. Elderly patients aged\u2009\u2265\u200975 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis. World J Urol. 2019;37(2):317\u201325. https:\/\/doi.org\/10.1007\/s00345-018-2389-1.","journal-title":"World J Urol"},{"issue":"Suppl 3","key":"6883_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/bju.14228","volume":"121","author":"S Vatandoust","year":"2018","unstructured":"Vatandoust S, Kichenadasse G, O\u2019Callaghan M, Vincent AD, Kopsaftis T, Walsh S, et al. Localised prostate cancer in elderly men aged 80\u201389\u00a0years, findings from a population\u2010based registry. BJU Int. 2018;121(Suppl 3):48\u201354. https:\/\/doi.org\/10.1111\/bju.14228.","journal-title":"BJU Int"},{"issue":"4","key":"6883_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.eururo.2016.12.025","volume":"72","author":"JP Droz","year":"2017","unstructured":"Droz JP, Albrand G, Gillessen S, Hughes S, Mottet N, Oudard S, et al. Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology. Eur Urol. 2017;72(4):521\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2016.12.025.","journal-title":"Eur Urol"},{"issue":"2","key":"6883_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ijrobp.2008.01.017","volume":"72","author":"GS Merrick","year":"2008","unstructured":"Merrick GS, Wallner KE, Galbreath RW, Butler WM, Brammer SG, Allen ZA, et al. Prostate brachytherapy in men\u2009>\u2009or =\u200975 years of age. Int J Radiat Oncol Biol Phys. 2008;72(2):415\u201320. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.01.017.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"6883_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, et al. NCCN Guidelines\u00ae insights: prostate Cancer, version 3.2024. J Natl Compr Cancer Network: JNCCN. 2024;22(3):140\u201350. https:\/\/doi.org\/10.6004\/jnccn.2024.0019.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"2","key":"6883_CR10","first-page":"78","volume":"6","author":"GS Merrick","year":"2000","unstructured":"Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: rationale, design, and evaluation. Tech Urol. 2000;6(2):78\u201384. PMID: 10798804.","journal-title":"Tech Urol"},{"issue":"7","key":"6883_CR11","doi-asserted-by":"publisher","first-page":"e0287218","DOI":"10.1371\/journal.pone.0287218","volume":"18","author":"A Visaria","year":"2023","unstructured":"Visaria A, Setoguchi S. Body mass index and all-cause mortality in a 21st century U.S. population: a national health interview survey analysis. PLoS ONE. 2023;18(7):e0287218. https:\/\/doi.org\/10.1371\/journal.pone.0287218.","journal-title":"PLoS ONE"},{"key":"6883_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110763","volume":"205","author":"YH Kim","year":"2025","unstructured":"Kim YH, Jeong JU, Yang JH, Nam TK, Song JY, Yoon MS, et al. Comparison of definitive radiotherapy outcomes between younger and older patients with high- or very-high-risk prostate cancer. Radiother Oncol. 2025;205:110763. https:\/\/doi.org\/10.1016\/j.radonc.2025.110763.","journal-title":"Radiother Oncol"},{"key":"6883_CR13","doi-asserted-by":"publisher","unstructured":"L\u00f6ffeler S, Bertilsson H, M\u00fcller C, Aas K, Haugnes HS, Aksness\u00e6ther B et al. Scandinavian prostate cancer group (SPCG) and the Norwegian Get-Randomized (GRand) initiative (2024). Protocol of a randomized, controlled trial comparing immediate curative therapy with Conservative treatment in men aged\u2009\u2265\u200975 years with non-metastatic high-risk prostate cancer (SPCG 19\/GRand-P). BJU Int, 133(6), 680\u20139. https:\/\/doi.org\/10.1111\/bju.1631","DOI":"10.1111\/bju.1631"},{"issue":"1","key":"6883_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.brachy.2009.06.008","volume":"9","author":"AV Taira","year":"2010","unstructured":"Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE. Factors impacting all-cause mortality in prostate cancer brachytherapy patients with or without androgen deprivation therapy. Brachytherapy. 2010;9(1):42\u20139. https:\/\/doi.org\/10.1016\/j.brachy.2009.06.008.","journal-title":"Brachytherapy"},{"issue":"10","key":"6883_CR15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.7326\/0003-4819-158-10-201305210-00005","volume":"158","author":"TJ Daskivich","year":"2013","unstructured":"Daskivich TJ, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med. 2013;158(10):709\u201317. https:\/\/doi.org\/10.7326\/0003-4819-158-10-201305210-00005.","journal-title":"Ann Intern Med"},{"issue":"3","key":"6883_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.eururo.2022.12.021","volume":"83","author":"TM Seibert","year":"2023","unstructured":"Seibert TM, Garraway IP, Plym A, Mahal BA, Giri V, Jacobs MF, et al. Genetic risk prediction for prostate cancer: implications for early detection and prevention. Eur Urol. 2023;83(3):241\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2022.12.021.","journal-title":"Eur Urol"},{"issue":"2","key":"6883_CR17","doi-asserted-by":"publisher","first-page":"e210070","DOI":"10.1001\/jamanetworkopen.2021.0070","volume":"4","author":"L Sun","year":"2021","unstructured":"Sun L, Parikh RB, Hubbard RA, Cashy J, Takvorian SU, Vaughn DJ, et al. Assessment and management of cardiovascular risk factors among US veterans with prostate cancer. JAMA Netw Open. 2021;4(2):e210070. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0070.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"6883_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.eururo.2015.12.032","volume":"70","author":"CM Friedenreich","year":"2016","unstructured":"Friedenreich CM, Wang Q, Neilson HK, Kopciuk KA, McGregor SE, Courneya KS. Physical activity and survival after prostate cancer. Eur Urol. 2016;70(4):576\u201385. https:\/\/doi.org\/10.1016\/j.eururo.2015.12.032.","journal-title":"Eur Urol"},{"issue":"3","key":"6883_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.eururo.2022.04.015","volume":"82","author":"A Affentranger","year":"2022","unstructured":"Affentranger A, Matulewicz RS, Fankhauser CD. Why and how smoking cessation must be implemented in urology clinics as a standard of care. Eur Urol. 2022;82(3):245\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2022.04.015.","journal-title":"Eur Urol"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-06883-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-025-06883-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-06883-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:37:38Z","timestamp":1769690258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12877-025-06883-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6883"],"URL":"https:\/\/doi.org\/10.1186\/s12877-025-06883-9","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by the BERACC Bethany Ethical Research & Animal Care Committee. All patients signed an IRB approved consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients signed an IRB approved consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Shalini Moningi has no conflicts to report.Grgur Miri\u0107 has served as a consultant for Theragenics, outside of the submitted work.Robert Galbreath has received a grant from Theragenics for statistical analysis.Ryan Fiano has no conflicts to report.Kent Wallner has no conflicts to report.Mutlay Sayan has no conflicts to report.Peter Orio has received research funding, consulting fees, and stock for Palette Life Sciences, outside of the submitted work.Martin King has received research funding from Palette Life Sciences, Bayer Healthcare, andAstraZeneca, outside of the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}